Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
0.6001
-0.0573 (-8.72%)
Nov 16, 2026, 3:16 PM EST - Market open
Daré Bioscience Revenue
Daré Bioscience had revenue of $187.55K in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to $1.37M. In the year 2025, Daré Bioscience had annual revenue of $1.03M with 10,429.36% growth. That makes Daré Bioscience the 43,135th largest company in the world by revenue and 5,957th in the United States.
Revenue (ttm)
$1.37M
Revenue Growth
+10,429.36%
P/S Ratio
9.47
Revenue / Employee
$56,914
Employees
24
Market Cap
11.80M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.03M | 1.02M | 10,429.36% |
| Dec 31, 2024 | 9.78K | -2.80M | -99.65% |
| Dec 31, 2023 | 2.81M | -7.19M | -71.92% |
| Dec 31, 2022 | 10.00M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 80.00K | 74.00K | 1,233.33% |
| Dec 31, 2013 | 6.00K | -619.00K | -99.04% |
| Dec 31, 2012 | 625.00K | 619.00K | 10,316.67% |
| Dec 31, 2011 | 6.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aligos Therapeutics | 33.65M |
| Radiopharm Theranostics | 8.90M |
| Kyntra Bio | 4.62M |
| Dyadic International | 3.80M |
| Pluri | 1.46M |
| Neuphoria Therapeutics | 1.17M |
| BioCardia | 3.00K |
| Fractyl Health | 3.00K |
DARE News
- 6 hours ago - Daré Bioscience Receives Approximately $852,000 in Additional Grant Funding - GlobeNewsWire
- 5 days ago - Daré Bioscience Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 6 days ago - Daré Bioscience Transcript: EGM 2026 - Transcripts
- 6 days ago - Daré Bioscience to Host Third Quarter 2026 Financial Results and Company Update Conference Call and Webcast on November 16, 2026 - GlobeNewsWire
- 7 days ago - Daré Bioscience Releases Next Episode in “CEO Corner” Video Series - GlobeNewsWire
- 12 days ago - Daré Bioscience to Present at Stifel's 2026 Healthcare Conference - GlobeNewsWire
- 17 days ago - Dare Bioscience receives additional $1.5M funding installment for DARE-LARC1 - TheFly
- 17 days ago - Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum - GlobeNewsWire